

Pulmonary nodules, surgery or other medication

Volume 9 Issue 1 - 2023

Da-Yong Lu, Hong-Ying Wu

School of Life Sciences, Shanghai University, China

Correspondence: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai 200444, PR China, Email ludayon@shu.edu.cn

Received: November 30, 2022 | **Published:** January 09, 2023

Introduction

With the technical advance of computerized tomography, it was found that a lot of adults (70-90%) showed pulmonary nodules in normal people. It is still neglected in medical circle. How to tackle this problem with therapeutic means is a modern challenge. It means that there is a potential risk of human health in pulmonary nodules. Some doctors want to do something to reverse this evidence and possible pathologic consequences. Different therapeutics had been proposed for this clinical evidence, especially surgery. However, the effectiveness of these therapies will be seen a long period of times.

From our points of view, it is not a good thing to “treat” patients immediately without understanding the underlying mechanisms and pathological consequences of this phenomenon. At present, these nodules are at least not fatal according to current discovery. Before large understanding of its pathogenesis, it is not suitable for immediate radical treatments. According to our point of view, diagnostic and pathological study of this phenomenon is more than surgery removal. Drug development¹⁻³ and traditional medicine⁴⁻⁷ is very important.

It is proposed that this evidence is not 100% associated with malignancy. Human infection, mental health problems and underlying diseases could also be possible. Personalized medicine may be useful.^{8,9} Financial support is needed for the researches of this enigma.

Acknowledgments

None.

Conflicts of interest

The authors declared no conflicts of interest.

References

1. Lu DY, Lu TR, Chen EH, et al. Anticancer drug development, system updating and global participation. *Current Drug Therapy*. 2017;12(1):37-45.
2. Lu DY, Lu TR, Chen EH, et al. Keep up the pace of drug development evolution and expenditure. *Cancer Rep Rev*. 2018;2(5):165.
3. Lu DY, Lu TR. Anticancer drug development, challenge and dilemma. *Nurse Care Open Access J*. 2020;7(3):72-75.
4. Lu DY, Lu TR, Yarla NS, et al. Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug. *Studies in Natural Products Chemistry*. 2020;66:91-115.
5. Lu DY, Lu TR. Herbal medicine in new era. *Hos Pal Med Int Jnl*. 2019;3(4):125-130.
6. Agarwal N, Majee C, Chakraborty GS. Natural herbs as anticancer drugs. *Int J PharmTech Res*. 2012;4(3):1142-1153.
7. Pattannayak S. Plants in healthcare: past, present and future. *Explor Anim Med Res*. 2021;11(2):140-144.
8. Lu DY. Personalized cancer chemotherapy. An effective way for enhancing outcomes in clinics. *Elsevier*. 2015.
9. Lu DY, Lu TR, Che JY, et al. Individualized cancer therapy, future approaches. *Current Pharmacogenomics & Personalized Medicine*. 2018;16(2):156-163.